貨號(hào)：GS40474

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Unlike some other anti?EGFR antibodies, nimotuzumab exhibits intermediate affinity and is thought to bind preferentially to EGFR?overexpressing cells while sparing normal tissues with lower EGFR density, potentially reducing severe skin and gastrointestinal toxicities. It blocks ligand binding and receptor activation, inhibiting downstream signaling pathways (e.g., MAPK, PI3K/AKT) that drive tumor proliferation and survival. It is approved in several countries (e.g., China, India, Cuba, Argentina) for the treatment of squamous cell carcinoma of the head and neck, glioma, and nasopharyngeal carcinoma, often in combination with radiotherapy or chemotherapy.